Q1 EPS Estimate for Elevation Oncology Boosted by Analyst

Elevation Oncology, Inc. (NASDAQ:ELEV) – Equities researchers at HC Wainwright increased their Q1 2025 EPS estimates for shares of Elevation Oncology in a research report issued on Monday, March 10th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($0.21) per share for the quarter, up from their previous forecast of ($0.23). HC Wainwright currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for Elevation Oncology’s current full-year earnings is ($0.84) per share. HC Wainwright also issued estimates for Elevation Oncology’s Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.23) EPS, FY2025 earnings at ($0.90) EPS and FY2026 earnings at ($0.90) EPS.

Several other equities analysts have also issued reports on the stock. Stephens reissued an “overweight” rating and issued a $5.00 price target on shares of Elevation Oncology in a report on Friday, March 7th. William Blair restated an “outperform” rating and set a $5.00 price objective on shares of Elevation Oncology in a research note on Friday, March 7th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $7.00 target price on shares of Elevation Oncology in a report on Thursday, December 19th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $6.83.

Elevation Oncology Price Performance

Shares of ELEV stock opened at $0.49 on Wednesday. Elevation Oncology has a 12-month low of $0.41 and a 12-month high of $5.83. The firm has a market capitalization of $29.26 million, a price-to-earnings ratio of -0.60 and a beta of 1.37. The company has a quick ratio of 17.77, a current ratio of 17.77 and a debt-to-equity ratio of 0.45. The firm has a fifty day moving average of $0.63 and a 200-day moving average of $0.62.

Elevation Oncology (NASDAQ:ELEV) last announced its quarterly earnings results on Thursday, March 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.04.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Barclays PLC grew its holdings in shares of Elevation Oncology by 302.4% during the third quarter. Barclays PLC now owns 72,077 shares of the company’s stock valued at $43,000 after buying an additional 54,167 shares during the last quarter. SG Americas Securities LLC grew its holdings in shares of Elevation Oncology by 33.9% during the fourth quarter. SG Americas Securities LLC now owns 61,467 shares of the company’s stock valued at $35,000 after buying an additional 15,560 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Elevation Oncology by 7.6% during the third quarter. Geode Capital Management LLC now owns 1,110,085 shares of the company’s stock worth $666,000 after purchasing an additional 78,509 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Elevation Oncology by 175.9% during the third quarter. JPMorgan Chase & Co. now owns 61,334 shares of the company’s stock worth $37,000 after purchasing an additional 39,101 shares during the last quarter. Finally, State Street Corp boosted its holdings in Elevation Oncology by 13.5% during the third quarter. State Street Corp now owns 1,018,026 shares of the company’s stock worth $611,000 after purchasing an additional 120,993 shares during the last quarter. 83.70% of the stock is currently owned by institutional investors and hedge funds.

Elevation Oncology Company Profile

Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.